美国FDA扩大了FUROSCIX治疗慢性心力衰竭患者的药物适用范围,包括NYHA IV类. US FDA expands FUROSCIX drug indication for congestion in chronic heart failure patients, including NYHA Class IV.

scPharmaceuticals宣布美国FDA已批准其药物FUROSCIX的扩展适用范围,该药物用于治疗慢性心力衰竭的成年患者因过多液体而导致的血栓塞,包括NYHA类IV患者. scPharmaceuticals announced that the US FDA has approved an expanded indication for its drug FUROSCIX, which treats congestion due to fluid overload in adult patients with chronic heart failure, including those in NYHA Class IV. 该决定旨在防止与心脏病有关的住院或重诊,并反映该药物在治疗心脏病患者方面的既定功效和安全性。 The decision aims to prevent heart failure-related hospital admissions or readmissions and reflects the drug's established efficacy and safety in treating heart failure patients. 这一扩大的指数覆盖了美国大约10%的心脏病患者。 This expanded indication covers around 10% of heart failure patients in the US. 然而,在市场开放之前,制药业的份额下降了约9.7%。 However, shares of scPharmaceuticals were down around 9.7% before the market opened.